GO:2000645 negative regulation of receptor catabolic process: Receptor Stability Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000645 (negative regulation of receptor catabolic process) describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of receptor breakdown.
• This regulatory node controls the half-life of cell-surface and intracellular receptors, thereby tuning signal transduction amplitude and duration.
• SOCS proteins are canonical negative regulators of receptor tyrosine kinase signaling and promote receptor degradation, illustrating the balance between receptor stabilization and catabolism.
• TULA-family proteins regulate platelet activation by modulating receptor catabolism and downstream signaling.
• Dysregulated receptor catabolism contributes to cancer, immune disorders, and metabolic disease, making GO:2000645 a therapeutic target space.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of genes that negatively regulate receptor catabolic process.
Description
GO:2000645, negative regulation of receptor catabolic process, is a biological_process term that captures any mechanism which stops, prevents, or reduces the frequency, rate, or extent of receptor catabolic process. Receptors are dynamic proteins whose abundance at the cell surface and in intracellular compartments determines the strength and duration of signaling. When receptor catabolism is unchecked, cells lose responsiveness to ligands; when it is excessively suppressed, receptors accumulate and signaling can become oncogenic or inflammatory. Therefore, understanding the negative regulation of receptor catabolic process is central to cell biology and pharmacology. The term is supported by experimental evidence across multiple receptor families, including receptor tyrosine kinases, G protein-coupled receptors, and cytokine receptors. For example, SOCS proteins negatively regulate receptor tyrosine kinase signaling by promoting receptor degradation, which is the opposite arm of the same equilibrium. TULA-family proteins modulate platelet activation through effects on receptor catabolism and signaling. In drug discovery, targeting receptor catabolism has produced clinical candidates such as vepdegestrant, a proteolysis-targeting chimera that degrades estrogen receptor. These examples underscore why GO:2000645 is a critical annotation for interpreting receptor biology and for designing experiments that manipulate receptor stability.
negative regulation of receptor catabolic process At A Glance
| GO ID | GO:2000645 |
|---|---|
| GO term | negative regulation of receptor catabolic process |
| Ontology | biological_process |
| Synonym | negative regulation of receptor breakdown; negative regulation of receptor catabolism; negative regulation of receptor degradation |
| Definition | Any process that stops, prevents or reduces the frequency, rate or extent of receptor catabolic process. |
| Major function | Controls receptor half-life and signaling amplitude by opposing receptor degradation |
| Related process | Receptor catabolic process, protein catabolic process, signal transduction |
| Example regulators | SOCS proteins, TULA-family proteins, cytokine receptor-like factors |
| Disease relevance | Cancer, immune dysregulation, metabolic and cardiovascular disorders |
What Is GO:2000645?
In plain terms, GO:2000645 describes the cellular brakes that slow down the destruction of receptors. The official QuickGO definition states: Any process that stops, prevents or reduces the frequency, rate or extent of receptor catabolic process. This includes mechanisms that inhibit receptor ubiquitination, block lysosomal or proteasomal delivery, or stabilize receptors through post-translational modifications or binding partners. The term is a negative regulatory node, meaning it does not itself degrade receptors but instead opposes the catabolic machinery. Synonyms include negative regulation of receptor breakdown, negative regulation of receptor catabolism, and negative regulation of receptor degradation. Because receptor catabolic process is itself a child of protein catabolic process, GO:2000645 sits at the intersection of signal transduction and protein turnover.
Why Is negative regulation of receptor catabolic process Important in Cell Biology?
Receptor abundance is a primary determinant of cellular responsiveness to hormones, growth factors, and cytokines. Negative regulation of receptor catabolic process sets the threshold for when a receptor is degraded versus preserved, and this balance directly affects signaling output. When this regulation fails, receptors can be prematurely destroyed, causing hormone resistance or immunodeficiency, or they can be stabilized abnormally, driving tumor growth and chronic inflammation. The term is therefore important for understanding both normal physiology and disease mechanisms, and it provides a framework for therapeutic strategies that either block or enhance receptor degradation.
• Controls the duration and intensity of receptor tyrosine kinase signaling by opposing receptor degradation.
• Regulates G protein-coupled receptor signaling, as shown for alpha2-adrenergic receptor-mediated Gi signaling.
• Modulates platelet activation through TULA-family proteins that influence receptor catabolism.
• Impacts antiviral immunity via cytokine receptor-like factor 3, which negatively regulates TBK1 degradation.
• Provides a mechanistic basis for proteolysis-targeting chimeras such as vepdegestrant that degrade estrogen receptor.
• Relevant to bone growth disorders, as vosoritide illustrates the therapeutic importance of receptor signaling balance.
• Connects to strigolactone perception in rice, showing that receptor turnover control is conserved in plants.
• Influences estrogen homeostasis through ERK1/2-RSK signaling, which intersects with receptor stability.
• Offers targets for cancer therapy where receptor stabilization drives proliferation.
• Guides CRISPR model design to test causal roles of receptor catabolism regulators.
What Happens During negative regulation of receptor catabolic process?
Recognition of receptors destined for catabolism
In simple terms: The cell first tags receptors that are meant to be destroyed.
Receptor catabolic process begins when receptors are recognized by ubiquitin ligases or sorting machinery that mark them for degradation. Negative regulation of this process can occur at the recognition step, for example when a binding partner masks the degradation signal or when a deubiquitinase removes the tag. SOCS proteins are classic examples of regulators that recognize receptor tyrosine kinases and promote their degradation, so their inhibition would oppose catabolism. The balance between tagging and untagging determines whether the receptor is routed to lysosomes or proteasomes.
Inhibition of receptor ubiquitination
In simple terms: Some proteins put a chemical block on the destruction tag.
Ubiquitination is a key signal for receptor catabolism. Negative regulation of receptor catabolic process can be achieved by preventing the addition of ubiquitin chains to the receptor cytoplasmic tail. This may involve competitive binding by a decoy protein, conformational changes that hide lysine residues, or recruitment of deubiquitinating enzymes. TULA-family proteins have been implicated in regulating platelet activation and may influence receptor ubiquitination states. Such mechanisms preserve receptor levels and prolong signaling.
Blocking lysosomal and proteasomal delivery
In simple terms: Even tagged receptors can be rescued before they reach the cellular trash can.
After ubiquitination, receptors are typically sorted to lysosomes or proteasomes. Negative regulation can occur by diverting receptors away from these compartments or by slowing their transport. For example, interactions with sorting nexins or retromer components can recycle receptors back to the plasma membrane instead of allowing degradation. In platelets, TULA-family proteins modulate receptor catabolism and downstream activation, suggesting that delivery steps are regulated. This level of control allows cells to rapidly adjust receptor surface levels without new protein synthesis.
Stabilization by post-translational modifications
In simple terms: Chemical modifications can act like a shield against destruction.
Phosphorylation, glycosylation, and other modifications can protect receptors from catabolism. For instance, ERK1/2-RSK signaling influences estrogen homeostasis and may affect receptor stability through phosphorylation. Negative regulation of receptor catabolic process includes such modifications that reduce the efficiency of degradation machinery. These modifications can be dynamic and reversible, providing a fast switch for receptor preservation.
Regulation by dedicated negative regulators
In simple terms: Specialized proteins act as bodyguards for receptors.
Dedicated negative regulators such as SOCS proteins, TULA-family proteins, and cytokine receptor-like factors can directly oppose receptor catabolism. Cytokine receptor-like factor 3 negatively regulates antiviral immunity by promoting TBK1 degradation, which is an example of catabolism regulation affecting immune signaling. In plants, strigolactone perception involves regulated receptor turnover, indicating evolutionary conservation. These regulators often act as scaffolds or adaptors that compete with degradation machinery.
Key Genes Involved in GO:2000645 negative regulation of receptor catabolic process
The following genes and proteins have been experimentally linked to negative regulation of receptor catabolic process or to the opposing catabolic machinery, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SOCS1 | Negative regulator of cytokine receptor signaling; promotes receptor degradation | KO models reveal enhanced receptor stability and signaling |
| SOCS3 | Modulates receptor tyrosine kinase catabolism | Point mutations can dissect SOCS box function |
| CISH | Cytokine-inducible SH2-containing protein; regulates receptor turnover | Overexpression stabilizes receptors |
| TULA-2 | Regulates platelet activation and receptor catabolism | KO platelets show altered receptor levels |
| TULA | Family of regulators of platelet activation | Knock-in tags enable trafficking studies |
| CRLF3 | Negatively regulates antiviral immunity by promoting TBK1 degradation | KO fish models show enhanced antiviral response |
| TBK1 | Kinase targeted for degradation by CRLF3 | Point mutation of ubiquitination sites |
| ADRB2 | Alpha2-adrenergic receptor-mediated Gi signaling | Overexpression and KO in signaling assays |
| ARRB1 | Beta-arrestin 1; scaffolds receptor internalization | KO affects receptor catabolism |
| ARRB2 | Beta-arrestin 2; regulates receptor trafficking | Point mutations alter receptor stability |
| ER | Estrogen receptor; degraded by vepdegestrant | Knock-in of degron tags |
| AR | Androgen receptor; catabolism affects prostate cancer | Overexpression models for degradation |
| DDB1 | Cullin-RING ligase component for receptor ubiquitination | KO reduces receptor catabolism |
| CUL5 | Scaffold for SOCS-box E3 ligases | Point mutation of SOCS box |
| RBX2 | RING finger protein in E3 ligases | Knockout affects receptor turnover |
| UBB | Ubiquitin precursor; tag for catabolism | Knock-in of tagged ubiquitin |
| PSMD1 | Proteasome subunit; executes catabolism | KO impairs receptor degradation |
| LAMP1 | Lysosomal marker; terminal catabolism | Tagged knock-in for imaging |
How Is negative regulation of receptor catabolic process Regulated?
Negative regulation of receptor catabolic process is itself regulated at multiple levels. Transcriptionally, SOCS genes are induced by cytokines, creating a feedback loop that limits receptor signaling. Post-translationally, phosphorylation of SOCS proteins can alter their stability and activity. In platelets, TULA-family proteins are regulated by tyrosine phosphorylation and interact with SH2 domains. Cytokine receptor-like factor 3 expression is modulated during antiviral responses, affecting TBK1 degradation. Additionally, ERK1/2-RSK signaling influences estrogen homeostasis and may intersect with receptor catabolism. These layers allow cells to fine-tune receptor half-life in response to environmental cues.
negative regulation of receptor catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ESR1 | Breast cancer; estrogen receptor degradation | Knock-in of degron tag; overexpression |
| SOCS1 | Inflammation and autoimmunity | KO and point mutation |
| CRLF3 | Antiviral immunity | KO in teleost fish |
| ADRB2 | Hypertension and metabolic disease | Overexpression and KO |
| TULA-2 | Platelet disorders | KO platelets |
Cancer
Receptor stabilization is a hallmark of many cancers. For example, estrogen receptor degradation is targeted by vepdegestrant, a proteolysis-targeting chimera, in breast cancer. SOCS proteins, which promote receptor tyrosine kinase degradation, are often silenced in tumors, leading to enhanced growth factor signaling. Understanding negative regulation of receptor catabolic process can reveal resistance mechanisms and new therapeutic targets.
Immune and inflammatory disorders
Cytokine receptor catabolism controls the duration of inflammatory signaling. SOCS proteins are critical negative regulators of cytokine receptors, and their dysfunction is linked to autoimmunity and chronic inflammation. Cytokine receptor-like factor 3 negatively regulates antiviral immunity by promoting TBK1 degradation, highlighting the importance of catabolism control in host defense. Modulating these pathways could treat cytokine storms or immunodeficiency.
Metabolic and cardiovascular disease
Receptor catabolism affects hormone sensitivity. Alpha2-adrenergic receptor-mediated Gi signaling is negatively regulated by a novel pathway, which may influence blood pressure and metabolic rate. Estrogen homeostasis is regulated by ERK1/2-RSK signaling, and altered receptor turnover could contribute to metabolic syndrome. Targeting these mechanisms may improve insulin sensitivity and cardiovascular health.
From negative regulation of receptor catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate receptor catabolism? | CRISPR knockout |
| Which domain is required for receptor stabilization? | Point mutation |
| How does tagged receptor traffic? | Knock-in of fluorescent tag |
| Does overexpression mimic disease? | Overexpression |
| What is the receptor half-life? | Tagged knock-in with pulse-chase |
| Which E3 ligase opposes the regulator? | Library screening |
How to Study the negative regulation of receptor catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene requirement for receptor catabolism | Identify negative regulators |
| Proteomics | Receptor half-life and ubiquitination | Quantify catabolism rates |
| Live-cell imaging | Receptor trafficking and localization | Visualize degradation blockade |
| RNA-seq | Transcriptional responses | Pathway analysis |
| Co-immunoprecipitation | Protein-protein interactions | Find receptor-regulator complexes |
| Pulse-chase | Receptor turnover kinetics | Measure stabilization |
| Flow cytometry | Surface receptor levels | Quantify catabolism inhibition |
| Bioinformatics | Motif and network prediction | Prioritize candidate genes |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify genes whose loss alters receptor catabolism. For example, knocking out SOCS genes may stabilize receptors and enhance signaling. Such screens are powerful for discovering novel negative regulators of receptor catabolic process.
Proteomics and interactomics
Mass spectrometry-based proteomics can quantify receptor half-life and identify ubiquitination sites. Affinity purification of receptor complexes can reveal interacting negative regulators such as TULA-family proteins. These methods provide unbiased views of catabolism regulation.
Imaging and trafficking assays
Fluorescently tagged receptors in knock-in cell lines allow live-cell imaging of endocytosis, recycling, and degradation. This reveals how negative regulators divert receptors from lysosomes. Co-localization with lysosomal markers like LAMP1 confirms catabolism blockade.
Transcriptomics and bioinformatics
RNA-seq after perturbation of candidate regulators can reveal downstream transcriptional changes. Bioinformatics analysis of receptor degradation motifs and ubiquitination sites can predict regulatory nodes. Integrating with public databases like QuickGO helps annotate GO:2000645.
How CRISPR Can Be Used to Study GO:2000645 negative regulation of receptor catabolic process
Knockout
CRISPR knockout of candidate negative regulators can stabilize receptors and prolong signaling. For example, knocking out SOCS1 may increase cytokine receptor levels. This approach tests necessity of the regulator in receptor catabolism.
Point Mutation
Point mutations can dissect functional domains. Mutating the SOCS box of SOCS proteins abolishes their ability to promote receptor degradation, thereby affecting negative regulation. Such models are valuable for structure-function studies.
Knock-in
Knock-in of fluorescent or degron tags allows real-time tracking of receptor catabolism. Tagging endogenous receptors with Halo or GFP enables imaging of degradation blockade. This provides physiological expression levels.
Overexpression
Overexpression of negative regulators can protect receptors from degradation and enhance signaling. For instance, overexpressing TULA-family proteins may alter platelet receptor levels. This models gain-of-function states seen in disease.
How EDITGENE Supports negative regulation of receptor catabolic process Research
Researchers studying negative regulation of receptor catabolic process-related genes often need to determine whether a candidate gene is causally involved in receptor stabilization or degradation. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of receptor catabolic process research.
Frequently Asked Questions About negative regulation of receptor catabolic process
What is GO:2000645?
GO:2000645 is the Gene Ontology term for negative regulation of receptor catabolic process, defined as any process that stops, prevents or reduces the frequency, rate or extent of receptor catabolic process.
What genes are involved in negative regulation of receptor catabolic process?
Key genes include SOCS1, SOCS3, CISH, TULA-family proteins, and CRLF3, which modulate receptor degradation.
How does negative regulation of receptor catabolic process affect cancer?
It can stabilize oncogenic receptors such as estrogen receptor, and drugs like vepdegestrant target receptor degradation in breast cancer.
What is the difference between receptor catabolism and its negative regulation?
Receptor catabolism is the breakdown of receptors, while negative regulation slows or prevents this breakdown, preserving receptor levels.
Which diseases are linked to receptor catabolism dysregulation?
Cancer, immune disorders, and metabolic diseases are linked to altered receptor catabolism.
What methods study negative regulation of receptor catabolic process?
CRISPR screens, proteomics, live-cell imaging, and RNA-seq are commonly used.
How do SOCS proteins regulate receptor catabolism?
SOCS proteins promote receptor degradation, so their inhibition would negatively regulate catabolism.
Can CRISPR knockout models help study receptor catabolism?
Yes, knocking out candidate regulators can reveal their necessity in receptor stabilization.
What is the role of TULA-family proteins in receptor catabolism?
TULA-family proteins regulate platelet activation and influence receptor catabolism.
How does CRLF3 affect antiviral immunity?
CRLF3 negatively regulates antiviral immunity by promoting TBK1 degradation, linking catabolism to immune signaling.
Conclusion
GO:2000645, negative regulation of receptor catabolic process, is a fundamental biological process that controls receptor half-life and signaling duration. Its dysregulation contributes to cancer, immune disorders, and metabolic disease, making it a rich area for therapeutic intervention. CRISPR-based models are indispensable for dissecting the causal roles of genes such as SOCS1, TULA-2, and CRLF3 in this process. By combining knockout, point mutation, knock-in, and overexpression strategies, researchers can map the regulatory networks that preserve or destroy receptors, ultimately guiding drug discovery.
References
- 1. Hu Q et al.. 2024. Regulatory mechanisms of strigolactone perception in rice.. Cell 187(26):7551-7567.e17 PMID: 39500324
- 2. Duggan S. 2021. Vosoritide: First Approval.. Drugs 81(17):2057-2062 PMID: 34694597
- 3. Wright EB et al.. 2023. ERK1/2-RSK regulation of oestrogen homeostasis.. FEBS J 290(8):1943-1953 PMID: 35176205
- 4. Kazi JU et al.. 2014. SOCS proteins in regulation of receptor tyrosine kinase signaling.. Cell Mol Life Sci 71(17):3297-310 PMID: 24705897
- 5. Tang C et al.. 2026. Insights Into Vepdegestrant (ARV-471): The First-in-Class Estrogen Receptor Proteolysis-Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer.. ChemMedChem 21(6):e202501111 PMID: 41866773
- 6. Yan X et al.. 2023. Cytokine Receptor-Like Factor 3 Negatively Regulates Antiviral Immunity by Promoting the Degradation of TBK1 in Teleost Fish.. J Virol 97(1):e0179222 PMID: 36515543
- 7. Kunapuli SP et al.. 2022. TULA-Family Regulators of Platelet Activation.. Int J Mol Sci 23(23) PMID: 36499237
- 8. Takesono A et al.. 1999. Negative regulation of alpha2-adrenergic receptor-mediated Gi signalling by a novel pathway.. Biochem J 343 Pt 1(Pt 1):77-85 PMID: 10493914
